SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as the community reacts to the recent finalization of its strategic Ask Sage acquisition, significantly bolstering its secure Generative AI capabilities for defense and regulated sectors. Investors are actively debating the implications of this growth, alongside ongoing discussions surrounding a postponed shareholder vote for increased authorized shares and the anticipation of new government contracts.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending amidst fierce debate over its impending January 15, 2026, shareholder meeting, which includes a contentious vote on significantly increasing authorized shares and executive compensation. Investors are sharply split, with optimists highlighting BMNR's substantial Ethereum holdings and long-term crypto potential, while critics decry persistent share dilution and the stock's underperformance against ETH, particularly as it trades below its net asset value.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership set to enhance global production and improve gross margins, alongside a private placement securing additional growth capital. The community is actively debating the stock's "low float monster" potential for a short squeeze against concerns about recent dilution. Traders are closely monitoring its significant price surge and high volume, with some anticipating further upside while others caution about volatility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe Coin is experiencing significant trending interest amid price volatility, sparking a lively debate between optimistic holders hoping for "zero-dropping" gains and strong skeptics calling it a "scam" or "garbage." The community is buzzing with hopes for substantial upward movement, often linking its potential to a broader meme crypto rally, despite widespread warnings about its past performance and current price levels.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending as a highly speculative low-float play, driven by its ongoing strategic review process and a significant cash position relative to its market capitalization. The community is actively discussing its potential for a short squeeze, often drawing comparisons to recent parabolic movers in the micro-cap space.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending following eased U.S. export restrictions for chipmaking equipment to its China fab, which investors view as a removal of a significant regulatory overhang ensuring operational stability. This clarity, coupled with robust and increasing demand for its advanced AI chip production from key clients like Nvidia and AMD, solidifies TSMC's indispensable role in the global semiconductor supply chain. The community is actively discussing how these factors underscore TSMC's market leadership amidst escalating AI infrastructure needs.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as the market reacts positively to its proposed spinoff and Hong Kong listing of its AI chip unit, Kunlunxin, further amplified by reports of Baidu's chips replacing Nvidia in Deepseek's operations. This move is widely seen by the community as a significant value-unlocking event for Baidu's comprehensive AI capabilities, including its robust autonomous driving division, positioning it strongly within China's strategic push for tech independence.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following the announcement of record-high vehicle deliveries for December and the fourth quarter, surpassing some competitors and nearing one million cumulative vehicles. The community is actively discussing the company's path to profitability and the value of its expanding battery swap network, though many express frustration over perceived market manipulation suppressing the stock's valuation despite strong fundamentals.

Memecoin on Injective taken over by the community.

Nonja

NONJA is a top-tier meme coin on the Injective blockchain, sparking intense community discussion due to its high liquidity and strong risk/reward profile. Traders are actively accumulating, viewing it as a leveraged play on Injective's robust ecosystem and impending catalysts, anticipating significant outperformance as the broader altcoin market strengthens.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors fiercely debate its market valuation amid widespread accusations of price manipulation and broker restrictions, despite the company's reported strong fundamentals and substantial contracts in the AI infrastructure space. With year-end tax-loss selling concluding, the community is closely watching for a potential major price movement, fueled by both bullish conviction in its growth trajectory and skeptical concerns about management's communication and past performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 186.2% in the 3rd quarter, according to the company in its most recent...

Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports...

Aptars Bidose Nasal System Delivers CARDAMYST (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the...

What is HC Wainwright's Estimate for MIST FY2026 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report...

Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 4,480 call options on the company. This is an...

<ul class="summary-bullets"><li>Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia and restore sinus rhythm.</li><li>The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.</li><li>Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter of 2026.</li></ul>Shares of Milestone Pharmaceuticals Inc. (MIST) rose nearly 32% in Monday’s pre-market after the company received approval from the U.S. Food and Drug Administration (FDA) for its first commercial product late Friday.Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia (PSVT) and restore sinus rhythm.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MIST">Milestone stock</a> trended in the ‘extremely bullish’ territory, while message volumes were at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Cardamyst Approval</h2>Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT. The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter (Q1) of 2026.“Cardamyst is a novel at-the-ready treatment option that addresses the unpredictable impact of PSVT by offering patients the freedom to manage episodes anytime and anywhere,” said Joseph Oliveto, CEO, Milestone Pharmaceuticals.<h2 class="st-heading-2">Clinical Data</h2>Milestone stated that Cardamyst’s approval by the FDA is based on safety data from more than 1,800 participants and over 2,000 episodes of PSVT.The company said that participants using Cardamyst were twice as likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster than with a placebo.<h2 class="st-heading-2">Retail Optimistic</h2>Retail users on Stocktwits expressed their optimism around the company and Cardamyst following the FDA approval.One user said that the most challenging part for the company was over after the approval, adding that those who are long on the stock have “ZERO to worry about here.”<stembedurl>https://stocktwits.com/Wut_About_Bob/message/639158529</stembedurl>Another user dismissed concerns that this is a “sell the news” event, adding that they are “waiting with 0 worries.”<stembedurl>https://stocktwits.com/MarketILF/message/639154331</stembedurl><a href="https://stocktwits.com/symbol/MIST">MIST stock</a> is up 2% year-to-date and 30% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-fully-priced-for-autonomy-ev-demand-weakens-gary-black/cLeECtqRE8s">Is TSLA Stock Fully Priced For Autonomy? Here's What Gary Black Thinks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Equity

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

FDA Approves Milestone Pharma' CARDAMYST, First Self-Administered Treatment For PSVT

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription...

Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of unusually large options trading on Monday. Traders bought 3,255 call options on the stock. This represents an increase...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIST News

MISTMilestone Pharmaceuticals Inc